Citigroup’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $438K | Sell |
29,261
-54,203
| -65% | -$811K | ﹤0.01% | 3011 |
|
2025
Q1 | $1.35M | Buy |
83,464
+9,712
| +13% | +$157K | ﹤0.01% | 2367 |
|
2024
Q4 | $1.72M | Buy |
73,752
+48,561
| +193% | +$1.13M | ﹤0.01% | 2231 |
|
2024
Q3 | $741K | Buy |
25,191
+5,871
| +30% | +$173K | ﹤0.01% | 2757 |
|
2024
Q2 | $454K | Sell |
19,320
-12,437
| -39% | -$292K | ﹤0.01% | 2760 |
|
2024
Q1 | $1.2M | Buy |
31,757
+21,460
| +208% | +$814K | ﹤0.01% | 2229 |
|
2023
Q4 | $222K | Buy |
+10,297
| New | +$222K | ﹤0.01% | 3132 |
|
2022
Q4 | – | Sell |
-25
| Closed | – | – | 5041 |
|
2022
Q3 | $0 | Sell |
25
-182
| -88% | – | ﹤0.01% | 5385 |
|
2022
Q2 | $3K | Buy |
207
+34
| +20% | +$493 | ﹤0.01% | 5007 |
|
2022
Q1 | $10K | Sell |
173
-303
| -64% | -$17.5K | ﹤0.01% | 4763 |
|
2021
Q4 | $56K | Buy |
476
+191
| +67% | +$22.5K | ﹤0.01% | 4239 |
|
2021
Q3 | $57K | Buy |
285
+86
| +43% | +$17.2K | ﹤0.01% | 3929 |
|
2021
Q2 | $35K | Buy |
199
+35
| +21% | +$6.16K | ﹤0.01% | 4318 |
|
2021
Q1 | $33K | Sell |
164
-239
| -59% | -$48.1K | ﹤0.01% | 4287 |
|
2020
Q4 | $79K | Buy |
403
+209
| +108% | +$41K | ﹤0.01% | 3834 |
|
2020
Q3 | $34K | Sell |
194
-153
| -44% | -$26.8K | ﹤0.01% | 3692 |
|
2020
Q2 | $80K | Sell |
347
-27
| -7% | -$6.23K | ﹤0.01% | 3582 |
|
2020
Q1 | $44K | Buy |
374
+70
| +23% | +$8.24K | ﹤0.01% | 3879 |
|
2019
Q4 | $58K | Buy |
304
+199
| +190% | +$38K | ﹤0.01% | 3867 |
|
2019
Q3 | $20K | Sell |
105
-193
| -65% | -$36.8K | ﹤0.01% | 4281 |
|
2019
Q2 | $51K | Buy |
298
+70
| +31% | +$12K | ﹤0.01% | 4080 |
|
2019
Q1 | $46K | Buy |
228
+60
| +36% | +$12.1K | ﹤0.01% | 4081 |
|
2018
Q4 | $32K | Sell |
168
-11
| -6% | -$2.1K | ﹤0.01% | 4181 |
|
2018
Q3 | $43K | Buy |
179
+85
| +90% | +$20.4K | ﹤0.01% | 4171 |
|
2018
Q2 | $25K | Buy |
+94
| New | +$25K | ﹤0.01% | 4299 |
|